{'fraction_non_alphanumeric': 0.01540436456996149, 'fraction_numerical': 0.0, 'mean_word_length': 5.666666666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Identifying and addressing unmet therapeutic needs in MS.

Current disease-modifying treatments in multiple sclerosis (MS) are partially effective in reducing relapses and slowing disease progression, but these treatments do not restore function and are effective mainly in relapsing forms of MS. Unmet needs in MS include treatments for progressive forms of MS, agents with improved efficacy and safety profiles and that comprehensively manage MS symptoms, and medications with neuroprotective or remyelinating properties. Some adverse effects of disease-modifying agents could be reduced if medications are developed with more specific treatment targets, and research into the pathogenesis of MS may lead to agents that could restore myelin or protect nerves from inflammation.